JUST IN: Mindray Rumored To Go Private In PE Buyout
This article was originally published in PharmAsia News
Executive Summary
China’s largest medical device maker, U.S.-listed Mindray, could be the latest healthcare company to delist and be taken private in a move to unlock value.
You may also be interested in...
China 'No' For Celgene's Paclitaxel A Major Blow To BeiGene
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.
Coronavirus Clash: Global Pharma Scrambles In Locking Down World
A former pharma executive shares views with Scrip about the coronavirus in China, the challenges facing corporations and individuals in a rapidly changing world and coming threats that could potentially cause even more damage than the pandemic.
China Clears First Coronavirus Vaccine Trial
Leveraging its Ebola vaccine success, Tianjin-based CanSino is looking to launch China’s first vaccine for COVID-19 as it secures permission to start local clinical trials.
Need a specific report? 1000+ reports available
Buy Reports